The best online stock broker. Open an account today and start earning up to $1000 of IBKR Stock !
Friday, February 4, 2022
Bayer will discontinue phase II development candidate eliapixant
Bayer will discontinue phase II development candidate eliapixantReview of development program led to reassessment of benefit-risk ratio in all four potential indications for the investigational P2X3 receptor antagonist
Berlin, Germany, February 4, 2022 – Bayer today announced the discontinuation of Phase II development candidate eliapixant (BAY 1817080), an investigational P2X3 receptor antagonist that was being evaluated for potential indications in endometriosis, refractory chronic cough, overactive bladder and diabetic neuropathic pain. Following a review of available data, Bayer concluded that the overall benefit no longer outweighs the risk in these indications.
Eliapixant is an investigational agent and has not been approved for use in any country, for any indication.
Thursday, February 3, 2022
Wednesday, February 2, 2022
Subscribe to:
Posts (Atom)